Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 3092Neoplasms 2436Carcinoma, Non-Small-Cell Lung 1863Prostatic Neoplasms 1617Colorectal Neoplasms 1422Lung Neoplasms 1292Multiple Myeloma 927Neoplasm Metastasis 919Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 847Ovarian Neoplasms 799Melanoma 783Carcinoma, Hepatocellular 736Stomach Neoplasms 639Brain Neoplasms 635Recurrence 633Squamous Cell Carcinoma of Head and Neck 630Head and Neck Neoplasms 609Glioblastoma 566Lymphoma 539Uterine Cervical Neoplasms 537Triple Negative Breast Neoplasms 504Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 497Hematologic Neoplasms 462Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 441Lymphoma, Non-Hodgkin 435Sarcoma 434

Interventions

toripalimab 1taletrectinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Non-small Lung Cancer × 1 year × Clear all
NCT07308106 2026-05-11

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
60 enrolled
Thoracic

Non-small Lung Cancer

NCT06293690 2025-12-18

Toripalimab Combined With SBRT for NSCLC

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Active not recruiting
40 enrolled
Thoracic

Non-small Lung Cancer

NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting
50 enrolled
Thoracic

Non-small Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡